ROLE OF DIACERIN IN DIFFERENT GRADES OF OSTEOARTHRITIS

MK NASEER; S FAISAL; AB BUTT; B AHMAD; MA RAO; S ASIF; A ALI; S AKRAM; A ARSHAD

doi:10.54112/bcsrj.v2023i1.743

Authors

MK NASEER Department of Orthopedics Surgery. King Edward Medical University, Lahore, Pakistan
S FAISAL Ghurki Trust Teaching Hospital, Lahore, Pakistan
AB BUTT Ghurki Trust Teaching Hospital, Lahore, Pakistan
B AHMAD Ghurki Trust Teaching Hospital, Lahore, Pakistan
MA RAO Ghurki Trust Teaching Hospital, Lahore, Pakistan
S ASIF King Edward Medical University, Mayo Hospital, Lahore, Pakistan
A ALI King Edward Medical University, Mayo Hospital, Lahore, Pakistan
S AKRAM Nawaz Sharif Medical College. Punjab Institute of Cardiology, Lahore, Pakistan
A ARSHAD Ghurki Trust Teaching Hospital, Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.743

Keywords:

Diacerein; Osteoarthritis; Efficacy; Improvement

Abstract

Osteoarthritis (OA) is a joint disease that causes pain and degeneration in the affected area. There are no standard guidelines for agents that can slow down or modify the disease's progress. Diacerin is one such agent used to improve symptoms of OA. The objective was to analyze its efficacy in different grades of OA. A quasi-experimental study was conducted at Ghurki Trust Teaching Hospital in Lahore over six months from Jan 2023 to July 2023. After obtaining informed consent and meeting inclusion and exclusion criteria, we included 78 patients with grade II and III OA (39 each). All patients were given Diacerin (100mg twice daily). The baseline Western Ontario and McMaster Universities Arthritis Index (WOMAC) and pain on the Visual Analogue Scale (VAS) were used to measure the treatment's efficacy in improving symptoms after six months. The data was analyzed using SPSS 23.0. The mean age of the participants was 53.98+6.17 years. The mean WOMAC score was 49.62+7.81 before treatment, which decreased significantly to 38.34+8.79 after six months of treatment (p-value <0.05). The mean VAS score before and after treatment was 7.41+0.98 and 4.82+1.07, respectively. These findings suggest that Diacerein significantly reduces pain and improves functional ability in patients with OA of the knee joint. This treatment was safe and well-tolerated. Its use is recommended in early grades of OA.

Downloads

Download data is not yet available.

References

Bartels, E. M., Bliddal, H., Schøndorff, P. K., Altman, R., Zhang, W., and Christensen, R. (2010). Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis and cartilage 18, 289-296.

Boileau, C., Tat, S. K., Pelletier, J.-P., Cheng, S., and Martel-Pelletier, J. (2008). Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis research & therapy 10, 1-10.

Cui, A., Li, H., Wang, D., Zhong, J., Chen, Y., and Lu, H. (2020). Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine 29.

Englund, M., Felson, D. T., Guermazi, A., Roemer, F. W., Wang, K., Crema, M. D., Lynch, J. A., Sharma, L., Segal, N. A., and Lewis, C. E. (2011). Risk factors for medial meniscal pathology on knee MRI in older US adults: a multicentre prospective cohort study. Annals of the rheumatic diseases 70, 1733-1739.

Fransen, M., Bridgett, L., March, L., Hoy, D., Penserga, E., and Brooks, P. (2011). The epidemiology of osteoarthritis in Asia. International journal of rheumatic diseases 14, 113-121.

Heller, G. Z., Manuguerra, M., and Chow, R. (2016). How to analyze the Visual Analogue Scale: Myths, truths and clinical relevance. Scandinavian journal of pain 13, 67-75.

Iqbal, M. N., Haidri, F. R., Motiani, B., and Mannan, A. (2011). Frequency of factors associated with knee osteoarthritis. JPMA-Journal of the Pakistan Medical Association 61, 786.

Kafil, N., Hadi, N. I., and Waseem, B. (2010). Comparison between glucosamine sulphate and nimesulide therapies in osteoarthritis. J Surg Pak 15, 97-102.

Kaur, D., Kaur, J., and Kamal, S. S. (2019). Diacerein, its beneficial impact on chondrocytes and notable new clinical applications. Brazilian Journal of Pharmaceutical Sciences 54, e17534.

Khan, R. M., Albutt, K., Qureshi, M. A., Ansari, Z., Drevin, G., Mukhopadhyay, S., Khan, M. A., Chinoy, M. A., Meara, J., and Hussain, H. (2019). Time-driven activity-based costing of total knee replacements in Karachi, Pakistan. BMJ open 9, e025258.

Kolesnichenko, V., Golka, G., Khanyk, T., and Veklych, V. (2021). Epidemiology of knee osteoarthritis. The Journal of VN Karazin Kharkiv National University, series" Medicine".

Kongtharvonskul, J., Anothaisintawee, T., McEvoy, M., Attia, J., Woratanarat, P., and Thakkinstian, A. (2015). Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. European journal of medical research 20, 1-11.

Louthrenoo, W., Nilganuwong, S., Aksaranugraha, S., Asavatanabodee, P., Saengnipanthkul, S., and Group, T. S. (2007). The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthritis and cartilage 15, 605-614.

Mabey, T., and Honsawek, S. (2015). Cytokines as biochemical markers for knee osteoarthritis. World journal of orthopedics 6, 95.

Mendes, A. F., Caramona, M. M., De Carvalho, A. P., and Lopes, M. C. (2002). Diacerhein and rhein prevent interleukin‐1β‐induced nuclear factor‐κB activation by inhibiting the degradation of inhibitor κB‐α. Pharmacology & toxicology 91, 22-28.

Nilsdotter, A., and Bremander, A. (2011). Measures of hip function and symptoms: Harris hip score (HHS), hip disability and osteoarthritis outcome score (HOOS), Oxford hip score (OHS), Lequesne index of severity for osteoarthritis of the hip (LISOH), and American Academy of orthopedic surgeons (AAOS) hip and knee questionnaire. Arthritis Care & Research 63, S200-S207.

Panova, E., and Jones, G. (2015). Benefit–risk assessment of diacerein in the treatment of osteoarthritis. Drug safety 38, 245-252.

Pelletier, J. P., Yaron, M., Haraoui, B., Cohen, P., Nahir, M. A., Choquette, D., Wigler, I., Rosner, I. A., and Beaulieu, A. D. (2000). Efficacy and safety of diacerein in osteoarthritis of the knee: A double‐blind, placebo‐controlled trial. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 43, 2339-2348.

Salehi-Abari, I. (2016). 2016 ACR revised criteria for early diagnosis of knee osteoarthritis. Autoimmune Dis Ther Approaches 3, 118.

Sharapova, E., Alekseeva, L., and Lila, A. (2018). Diacerein in the treatment of osteoarthritis in patients with comorbidity. Modern Rheumatology Journal 12, 54-58.

Siddique, S., Imran, Y., Rizwan, A., and Aaraj, S. (2021). Role of Diacerein in osteoarthritis. The Professional Medical Journal 28, 1552-1556.

Walker, L. C., Clement, N. D., and Deehan, D. J. (2019). Predicting the outcome of total knee arthroplasty using the WOMAC score: a review of the literature. The journal of knee surgery 32, 736-741.

Zhang, Z., Huang, C., Jiang, Q., Zheng, Y., Liu, Y., Liu, S., Chen, Y., Mei, Y., Ding, C., and Chen, M. (2020). Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition). Annals of translational medicine 8.